Critical Path to Tuberculosis Drug Regimens: Global collaboration to accelerate development of novel drug regimens and rapid drug susceptibility tests for tuberculosis
Vol 1, Issue 1, 2016, Article identifier:51-58
VIEWS - 507 (Abstract) 406 (PDF)
Abstract
Keywords
Full Text:
PDFReferences
WHO Global Tuberculosis Report 2014, viewed April 9, 2015,
Critical Path to Tuberculosis Drug Regimens, n.d., viewed April 9, 2015,
Tuberculosis Therapeutic Area User Guide v1, 2012, viewed April 9, 2015,
Qualification opinion: In-vitro hollow fiber system model of tuberculosis (HSF-TB), 2015, viewed April 9, 2015,
Jamei M, Marciniak S, Edwards D, et al. 2013, The Simcyp population based simulator: architecture, im-plementation, and quality assurance. In Silico Pharma-cology, vol.1(1): 1–14. http://dx.doi.org/10.1186/2193-9616-1-9.
Egelund E F, Weiner M, Singh R P, et al. 2014, Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy, vol.58(8): 4904–4910. http://dx.doi.org/10.1128/AAC.01730-13.
Peloquin C A, Jaresko G S, Yong C L, et al. 1997, Pop-ulation pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrobial Agents and Chemo-therapy, vol.41(12): 2670–2679.
Zhu M, Starke J R, Burman WJ, et al. 2002, Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy, vol.22(6): 686–695.
http://dx.doi.org/10.1592/phco.22.9.686.34067.
Parida S K and Kaufmann S H, 2010, The quest for biomarkers in tuberculosis. Drug Discovery Today, vol.15(3–4): 148–157. http://dx.doi.org/10.1016/j.drudis.2009.10.005.
Wallis R S, Doherty T M, Onyebujoh P, et al. 2009, Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet Infectious Diseases, vol.9(3): 162–172. http://dx.doi.org/10.1016/S1473-3099(09)70042-8.
Epstein M D, Schluger N W, Davidow A L, et al. 1998, Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients re-ceiving treatment for pulmonary tuberculosis. Chest, vol.113(2): 379–386. http://dx.doi.org/10.1378/chest.113.2.379.
Marino S and Kirschner D, 2004, The human immune response to Mycobacterium tuberculosis in lung and lymph node. Journal of Theoretical Biology, vol.227(4): 463–486. http://dx.doi.org/10.1016/j.jtbi.2003.11.023.
Darpo B, Benson C, Dota C, et al. 2015, Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clinical Pharmacology and Therapeutics, vol.97(4): 326–335. http://dx.doi.org/10.1002/cpt.60.
Johannesen L, Vicente J, Gray R A, et al. 2014, Im-proving the assessment of heart toxicity for all new drugs through translational regulatory science. Clinical Pharmacology and Therapeutics, vol.95(5): 501–508. http://dx.doi.org/10.1038/clpt.2013.238.
DOI: http://dx.doi.org/10.18063/jmds.v1i1.114
(507 Abstract Views, 406 PDF Downloads)
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Debra Hanna, Marco Schito, Klaus Romero

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.